摘要
目的观察卡维地洛对肥厚型心肌病患者心室重构的影响。方法将35例肥厚型心肌病患者随机分为卡维地洛组(21例)与对照组(14例),两组均予常规治疗,卡维地洛组加用卡维地洛,疗程4个月,并随访至半年。检测两组治疗前后氧化应激、炎症、超声及基质金属蛋白酶2(MMP-2)和特异性组织抑制剂2(TIMP-2)的改变情况以及半年内的不良心血管事件。结果治疗后两组氧化应激、炎症均较治疗前显著降低,心室重构减缓(P<0.05),而卡维地洛组尤为明显(P<0.01)。相比对照组,卡维地洛组的半年心血管不良事件更低(P<0.05)。结论卡维地洛可降低氧化应激、炎症,减缓肥厚型心肌病患者心室重构,减少心血管不良事件的发生。
Objective To investigate the effects of carvedilol on ventricular remodeling in patients with hypertrophic non - obstruc- tive eardiomyopathy （HNCM）. Methods Totally 35 patients with HNCM were randomly divided into the carvedilol group （n = 21） and the control group（ n = 140）. Each group was given traditional treatment while the carvedilol group was additionally treated with carvedilol for 4 months. The oxidative stress, inflammatory markers, echocardiography, matrix metalloproteinase 2 （MMP- 2）, tissue inhibits of metalloproteinase - 2 （TIMP - 2） were detected in both groups before and after treatment. All patients were followed up to 6 months. Re- suits After treatment, the oxidative stress, serum level of inflammatory cytokines and ventricular remodeling were improved （P 〈 0. 05） , especially in the carvedilol group （P 〈 0. 01 ）. Compared to the control group, lower cardiovascular adverse events were occurred in the carvedilol group （P 〈 0.05）. Conclusion Carvedilol can lower oxidative stress, serum level of inflammatory eytokine, reverse ventricu- lar remodeling and reduce adverse cardiovascular events in patients with HNCM.
出处
《医学研究杂志》
2013年第8期133-135,共3页
Journal of Medical Research
关键词
卡维地洛
肥厚型心肌病
氧化应激
炎症
心室重构
Carvedilol
Hypertrophic non - obstructive cardiomyopathy
Oxidative stress
Inflammation
Remodeling
